About BRISC complex subunit Abraxas 2
BRISC complex subunit Abraxas 2 (ABRAXAS2) is a protein
from Homo sapiens identified by UniProt accession
Q15018, 415 residues long.
MolForge cross-references it against 0 known binders and
76 disease associations.
Target properties
| Protein name | BRISC complex subunit Abraxas 2 |
|---|
| UniProt accession | Q15018 |
|---|
| Gene | ABRAXAS2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 415 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (76)
Diseases linked to this target (Open Targets).
- hematocrit · score 0.26
- creatinine measurement · score 0.20
- brain volume measurement · score 0.19
- hemoglobin measurement · score 0.16
- hippocampus molecular layer volume · score 0.15
- hippocampal CA3 volume · score 0.14
- body height · score 0.14
- hippocampal CA1 volume · score 0.14
- platelet count · score 0.12
- leukocyte count · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15018-F1 | alphafold | PREDICTED | 73.62 | — |
Amino-acid sequence (415 residues)
MAASISGYTF SAVCFHSANS NADHEGFLLG EVRQEETFSI SDSQISNTEF LQVIEIHNHQ PCSKLFSFYD YASKVNEESL DRILKDRRKK VIGWYRFRRN TQQQMSYREQ VLHKQLTRIL GVPDLVFLLF SFISTANNST HALEYVLFRP NRRYNQRISL AIPNLGNTSQ QEYKVSSVPN TSQSYAKVIK EHGTDFFDKD GVMKDIRAIY QVYNALQEKV QAVCADVEKS ERVVESCQAE VNKLRRQITQ RKNEKEQERR LQQAVLSRQM PSESLDPAFS PRMPSSGFAA EGRSTLGDAE ASDPPPPYSD FHPNNQESTL SHSRMERSVF MPRPQAVGSS NYASTSAGLK YPGSGADLPP PQRAAGDSGE DSDDSDYENL IDPTEPSNSE YSHSKDSRPM AHPDEDPRNT QTSQI
Explore BRISC complex subunit Abraxas 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets